Literature DB >> 28509144

A case of familial Mediterranean fever-associated systemic amyloidosis.

Norio Nakamura1,2, Takeshi Fujita3, Reiichi Murakami3, Ryuichiro Kumasaka3, Michiko Shimada3, Yuko Shimaya3, Hiroshi Osawa3, Hideaki Yamabe3, Ken Okumura3, Akihiro Yachie4.   

Abstract

Familial Mediterranean fever (FMF) is a chronic inflammatory disease, characterized by recurrent fever and polyserositis (pleuritis and/or peritonitis). The most important complication of FMF is amyloidosis, which causes chronic renal failure. Colchicine is the most effective treatment in acute attacks and amyloidosis development. However, the majority of patients with amyloidosis have a relentless progression to end-stage renal disease despite initiation of colchicine treatment. We present the case of a 38-year-old man with FMF-associated chronic renal failure due to systemic amyloidosis. The patient suffered from periodic fever and renal insufficiency, and was admitted to our hospital. Laboratory examination revealed an inflammatory reaction, renal dysfunction (serum creatinine 2.5 mg/dl), and proteinuria. Renal biopsy revealed segmental mesangial AA amyloid deposits in several glomeruli and the walls of several vessels. Genetic analysis showed that the patient was heterozygous for the MEFV gene (E148Q/M694I). Thus, he was diagnosed with FMF, and colchicine treatment was initiated. He remained almost attack free, with decreasing serum creatinine levels (1.6 mg/dl) and diminishing urinary protein excretion. In conclusion, renal amyloidosis is the most important long-term complication of FMF, and treatment with colchicine is effective for preventing progression. Therefore, colchicine treatment should be initiated as early as possible after the diagnosis of FMF.

Entities:  

Keywords:  Amyloidosis; Colchicine; Familial Mediterranean fever

Year:  2012        PMID: 28509144      PMCID: PMC5387864          DOI: 10.1007/s13730-011-0002-1

Source DB:  PubMed          Journal:  CEN Case Rep        ISSN: 2192-4449


  14 in total

Review 1.  Colchicine--expanding horizons.

Authors:  A Schattner
Journal:  Postgrad Med J       Date:  1991-03       Impact factor: 2.401

2.  Mechanism of the anti-inflammatory effect of colchicine in rheumatic diseases: a possible new outlook through microarray analysis.

Authors:  E Ben-Chetrit; S Bergmann; R Sood
Journal:  Rheumatology (Oxford)       Date:  2005-09-27       Impact factor: 7.580

3.  The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators.

Authors:  M Centola; G Wood; D M Frucht; J Galon; M Aringer; C Farrell; D W Kingma; M E Horwitz; E Mansfield; S M Holland; J J O'Shea; H F Rosenberg; H L Malech; D L Kastner
Journal:  Blood       Date:  2000-05-15       Impact factor: 22.113

Review 4.  Familial Mediterranean fever.

Authors:  Fatos Onen
Journal:  Rheumatol Int       Date:  2005-11-10       Impact factor: 2.631

5.  Criteria for the diagnosis of familial Mediterranean fever.

Authors:  A Livneh; P Langevitz; D Zemer; N Zaks; S Kees; T Lidar; A Migdal; S Padeh; M Pras
Journal:  Arthritis Rheum       Date:  1997-10

6.  ASC is an activating adaptor for NF-kappa B and caspase-8-dependent apoptosis.

Authors:  Junya Masumoto; Theresa A Dowds; Philip Schaner; Felicia F Chen; Yasunori Ogura; Mu Li; Li Zhu; Tsutomu Katsuyama; Junji Sagara; Shun'ichiro Taniguchi; Deborah L Gumucio; Gabriel Núñez; Naohiro Inohara
Journal:  Biochem Biophys Res Commun       Date:  2003-03-28       Impact factor: 3.575

7.  Familial Mediterranean fever in three Japanese patients, and a comparison of the frequency of MEFV gene mutations in Japanese and Mediterranean populations.

Authors:  Tomoko Sugiura; Yasushi Kawaguchi; Satoru Fujikawa; Yukiko Hirano; Toru Igarashi; Manabu Kawamoto; Kae Takagi; Masako Hara; Naoyuki Kamatani
Journal:  Mod Rheumatol       Date:  2007-12-22       Impact factor: 3.023

8.  Efficacy of colchicine therapy in amyloid nephropathy of familial Mediterranean fever.

Authors:  Ayşe Oner; Ozlem Erdoğan; Gülay Demircin; Mehmet Bülbül; Leyla Memiş
Journal:  Pediatr Nephrol       Date:  2003-04-16       Impact factor: 3.714

9.  Colchicine treatment of AA amyloidosis of familial Mediterranean fever. An analysis of factors affecting outcome.

Authors:  A Livneh; D Zemer; P Langevitz; A Laor; E Sohar; M Pras
Journal:  Arthritis Rheum       Date:  1994-12

10.  MEFV mutation analysis of familial Mediterranean fever in Japan.

Authors:  N Tomiyama; Y Higashiuesato; T Oda; E Baba; M Harada; M Azuma; T Yamashita; K Uehara; A Miyazato; K Hatta; Y Ohya; K Iseki; Y Jinno; S Takishita
Journal:  Clin Exp Rheumatol       Date:  2008 Jan-Feb       Impact factor: 4.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.